Fingolimod (FTY720), an immunomodulator, is approved as an oral treatment for patients with relapsing forms of multiple sclerosis. Its effects are largely attributed to its mechanism of selectively retaining lymphocytes in the lymph nodes to reduce autoreactive T-cell recruitment in the CNS. In this study, we investigated the therapeutic effect of FTY720 on an animal model of CNS inflammation induced by intracerebral ventricle LPS injection. We found that FTY720 treatment significantly prevented LPS-induced neutrophil recruitment in the CNS by inhibiting leukocyte recruitment in cerebral microvessels. Furthermore, FTY720 also inhibited the expressions of adhesion molecules on the cerebral endothelium, but did not affect the expression levels of pro-inflammatory cytokines (TNF-and IL-6) and chemokines (CXCL1 and CXCL2) in the CNS parenchyma. The inhibition of endothelial activation was accompanied by reduced phosphorylation of signaling molecules, including serine/threonine-specific protein kinase (Akt), STAT6, and nuclear factor-B. This FTY720-attenuated inhibition of leukocyte recruitment and endothelial activation was reversed by blocking the functions of sphingosine kinase 2 or sphingosine-1-phosphate receptor 1. Our study demonstrated, for the first time, that FTY720 directly inhibits the phosphorylation of multiple signaling molecules in endothelial cells, thereby effectively blocking leukocyte recruitment in the CNS.
activated by SphK2. 21 Phosphorylated FTY720 mediates the antagonistic effect by binding to S1P receptors, and causes their internalization from cell membranes, thereby rendering the immune cells insensitive to S1P gradients. 21, 22 The beneficial effects of FTY720 in many CNS inflammatory diseases have been widely reported. When administered daily, FTY720 significantly decreased A 42-induced learning and memory impairment, and prevents hippocampal neuronal damage and caspase-3 activation. 23 In a multicenter trial, combination therapy of FTY720 and alteplase significantly attenuated reperfusion injury and improved clinical outcomes in patients with hemispheric ischemic stroke. 24 In addition, FTY720 attenuated the neurological deficit and reduced infarct volume after in situ thromboembolic occlusion of the middle cerebral artery. 25 FTY720 also decreased microvascular permeability, attenuated neurological deficits, and promoted recovery in patients with acute and anterior cerebral circulation occlusion stroke. 26 More importantly, FTY720 is the first oral drug approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis. 27, 28 The dominant action of FTY720 is largely due to its efficacy to sequester autoreactive T cells in lymph nodes. 29 In addition, FTY720 regulates proinflammatory cytokine expression from glial cells, which is also likely to contribute to its protective effects in CNS inflammation. 30 However, other mechanisms implicated in immune cell trafficking could also possibly contribute to such therapeutic effects.
In our study, we systematically examined the effect of FTY720 on neutrophil recruitment in response to intracerebroventricular (i.c.v.) LPS administration. Neutrophil infiltration in the CNS parenchyma was blocked by targeting S1P signaling with FTY720. By using intravital microscopy and other approaches, we verified that FTY720 inhibited cerebral endothelial activation and subsequent leukocyte-endothelial interactions in cerebral microvessels in a SphK2-and S1P1-dependent manner, whereas the expression of proinflammatory cytokines and chemokines in the CNS was unaffected. FTY720 treatment also significantly reduced endothelial activation in vitro, as evidenced by decreased phosphorylation levels of serine/threonine-specific protein kinase (Akt), STAT6, and nuclear factor-B (NF-B). Therefore, targeting S1P1 and downstream signal activation in cerebral endothelial cells provides an effective strategy to block leukocyte recruitment, and therefore elicit beneficial effects in CNS inflammatory conditions.
MATERIALS AND METHODS

Animals and reagents
Wild-type male C57BL/6J mice (aged 6-8 weeks) were purchased from the Model Animal Research Center, Nanjing University. SphK2-deficient mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA). These mice were housed in specific pathogen-free conditions under a 12-h light/dark cycle at Nanjing Medical University Animal Facility, China. Experimental protocols were approved by the Animal Research Ethics Committee of Nanjing Medical University.
Ultrapure LPS (Escherichia coli serotype 0111:B4 strain) was purchased from InvivoGen (San Diego, CA, USA). FTY720 and W123
were purchased from Cayman Chemical (Ann Arbor, MI, USA). Tumor necrosis factor-(TNF-) was purchased from R&D Systems (Minneapolis, MN, USA). Antibodies (Abs) against E-selectin, VCAM-1, STAT6/p-STAT6, and mouse serum albumin were purchased from Abcam (Cambridge, MA, USA). Abs against P-selectin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Abs againstactin, NF-B, phospho-NF-B, Akt, and phospho-Akt were purchased from Cell Signaling Technology (Beverly, MA, USA).
Cell culture and treatment
The murine cerebral microvascular endothelial cell line bEND.3 was purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in DMEM/F12 (GE Healthcare HyClone, Logan, UT, USA) containing 10% FBS (Gibco, Gaithersburg, MD, USA) and 1% penicillin/streptomycin in a 37 • C, 5% CO 2 incubator. The cells were starved for 12 h and pretreated with FTY720 (5 M) for 30 min, and then cultured with 1 g/ml LPS for 1 h (to assess the signaling molecules) or 4 h (to assess the adhesion molecules). To determine whether the effect of FTY720 is mediated by S1P1, W123 (20 M) was added 30 min before LPS and FTY720 treatment.
Murine primary cerebral microvascular endothelial cells were isolated and cultured as previously described. 31 The endothelial cells reached 80-90% confluence after 7 days and the purity was >93%. The cells were then starved for 12 h before pretreated with FTY720 (5 M) for 30 min, and then cultured with 1 g/ml LPS for 1 h (to assess the signaling molecules) or 4 h (to assess the adhesion molecules).
Intracerebroventricular LPS injection
The mice were anesthetized by i.p. injecting a mixture of 200 mg/kg ketamine and 10 mg/kg xylazine; subsequently, the anesthetized mice were placed in a rodent stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA). After shaving the scalp, a burr hole was drilled 1 mm caudal to bregma and 2 mm lateral to the midline. LPS (2 g, in 2 l sterile saline) was injected using a 5-l Hamilton microsyringe into the left ventricle over a period of 5 min. Sham animals received an isovolumetric injection of saline. Body temperatures were measured using a rectal probe, and the mice were maintained under anesthesia throughout the experiment at 36 ± 1 • C by using a thermostatic heating blanket (Harvard Apparatus, Holliston, MA, USA).
Identification of neutrophil infiltration in the CNS
The mice were anesthetized with a mixture of ketamine and xylazine, and transcardially perfused with ice-cold 4% formalin. The brains were dissected and preserved in 4% formalin for at least 48 h. in the cortex and hippocampus were counted; neutrophils in the ventricles or meninges were excluded.
Intravital microscopy
Leukocyte recruitment in the brain was observed 4 h after LPS i.c.v.
injection. FTY720 i.p. injection was performed 1 h prior to LPS injection to allow the drug to penetrate through the blood-brain barrier (BBB)
into the CNS parenchyma. Intravital microscopy was performed as previously described. 32, 33 Briefly, a craniotomy was performed using a high-speed drill (Fine Science Tools, Foster City, CA, USA), and the dura mater was removed to expose the underlying pial vasculature. Leuko- 
Enzyme-linked immunosorbent assay
The mice were anesthetized before perfusion through the heart with ice-cold PBS. After decapitation, the brains were removed immediately and then homogenized in 1000 l of sterile PBS. The homogenate was centrifuged at 12,000 rpm at 4 • C for 5 min, and the supernatant was collected. TNF-, IL-6, CXCL1, and CXCL2 concentrations were determined using the quantitative sandwich ELISA (R&D Systems) according to the manufacturer's instructions.
RNA isolation and real-time quantitative PCR
Total RNA was extracted from the brain tissue using TRIzol reagent (Invitrogen Life Technologies, Gaithersburg, MD, USA) and reversetranscribed using Superscript II (Invitrogen Life Technologies). Realtime PCR was performed using SYBR green PCR reagent according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). The primer sets used for amplification were as follows:
Quantitative PCR was performed in an ABI Prism 7300 spectrofluorometric thermal cycler (Applied Biosystems) using SYBR green I as a double-strand DNA-specific binding dye. Quantitative PCR assays were conducted in triplicates for each sample and target mRNA levels were quantified using the 2 −ΔΔCt method. Results were normalized to 2 -MG transcript data.
Western blot
The brain tissue or endothelial cells were lysed in lysis buffer: 50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 0.5% sodium deoxycholate with protease inhibitors. The protein content of supernatants was determined using a BCA protein assay kit 
Phosphorylation microarray analysis
Phospho-array was performed in co-operation with Wayen Biotechnology (Shanghai, China). Four hours after LPS or LPS/FTY720 treat- F I G U R E 3 FTY720 reduced mRNA and protein expression levels of adhesion molecules in the brain vasculature during CNS inflammation. C57BL/6J mice were treated with saline, LPS (i.c.v. 2 g LPS for 4 h), or LPS plus FTY720 (pretreated with i.p. injected 1 mg/kg FTY720 for 1 h, and then treated with i.c.v. 2 g LPS for 4 h). Total RNA was extracted and the mRNA expression levels of P-selectin (A), E-selectin (B), and VCAM-1 (C) in the brain parenchyma were analyzed using quantitative RT-PCR. Data represent the mean ± SEM of relative mRNA levels normalized to 2-MG levels. Proteins were extracted from brain tissue; P-selectin (D), E-selectin (E), and VCAM-1 (F) levels were analyzed using Western blot analysis using specific antibodies. Images are representative of at least n = 4 experiments. Band intensity was quantified by densitometry and expressed as mean ± SEM; *P < 0.05, **P < 0.01 (vs. LPS-treated mice); n = 4-5 in all groups Instruments, Houston, TX, USA). The phosphorylation ratio was analyzed as follows: phosphorylation ratio = phospho value/unphospho value. The L + F/L ratio = LPS + FTY720 phosphorylation ratio/LPS phosphorylation ratio.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5 (Graphpad Software, Inc., San Diego, CA, USA). Data are presented as the mean ± SEM. A one-way analysis of variance (ANOVA) with simultaneous multiple comparisons among different groups was applied, and results with P < 0.05 were considered statistically significant.
RESULTS
FTY720 blocked LPS-induced neutrophil recruitment into the brain
To examine the effects of FTY720 on neutrophil recruitment induced by i.c.v. injection of LPS, mice received 5 i.p. injections of FTY720
(1 mg/kg body weight) at an interval of 4 h after being treated with LPS, and were sacrificed 24 h later (Fig. 1A) . The i.c.v. LPS injection resulted in significant neutrophil infiltration in the cortex (Fig. 1B) and hippocampus (Fig. 1C) . FTY720 treatment significantly reduced neutrophil recruitment in the cortex (Fig. 1D) and hippocampus (Fig. 1E) .
The numbers of infiltrating neutrophils in the cortex (Fig. 1F ) and hippocampus (Fig. 1G) induced by i.c.v. LPS were significantly reduced by FTY720 treatment. FTY720 treatment did not alter the levels of TNF-, IL-6, CXCL1, or CXCL2 in the brain (Supplementary Fig. 1 ).
To further explore the mechanisms through which FTY720 inhibits neutrophil recruitment, we performed intravital microscopy and investigated the leukocyte recruitment cascade in the brain vasculature. Saline-or FTY720-treated mice showed minimal leukocyteendothelial interactions in the postcapillary venules ( Fig. 2A) 
F I G U R E 5 FTY720 reduced the protein expression of adhesion molecules in murine cerebral endothelial cells in vitro.
Murine cerebral endothelial cells bEND.3 were incubated with FTY720, LPS, or LPS plus FTY720 as described in Section 2. The protein expression levels of Pselectin (A), E-selectin (B), and VCAM-1(C) were analyzed using Western blot analysis. The band intensity was quantified by densitometry after normalization with the total -actin protein levels. Images are representative of at least 3 experiments. Data represent the mean ± SEM of 3 independent experiments; *P < 0.05 recruitment (Fig. 2C, Supplementary Video 2) ; the numbers of rolling cells (Fig. 2D ) and adherent cells (Fig. 2E ) in FTY720 + LPS treated mice were reduced by over 80% compared with those observed in LPStreated mice. The reduction was also observed in TNF--induced neutrophil recruitment in cerebral microvessels ( Supplementary Fig. 2 ).
FTY720 inhibited endothelial activation in CNS inflammation
Endothelial cells express high levels of adhesion molecules when they are activated in an inflammatory environment; 34 as a result, neutrophils roll and adhere to the cerebral endothelium and transmigrate through the BBB. The mRNA and protein levels of the adhesion molecules in the brain significantly increased after the mice received LPS i.c.v. injection (Fig. 3A-F) . FTY720 treatment significantly blocked the mRNA expression of P-selectin (Fig. 3A) , E-selectin (Fig. 3B) , and VCAM-1 (Fig. 3C ) in LPS-treated animals. Western blot analysis also revealed a significant reduction in P-selectin (Fig. 3D ), E-selectin (Fig. 3E) , and VCAM-1 (Fig. 3F) 
F I G U R E 6
The inhibitory effect of FTY720 on endothelial activation was mediated by sphingosine kinase 2. C57BL/6J mice and sphingosine kinase 2-deficient mice were pretreated with i.p. injected FTY720 (1 mg/kg) for 1 h, and then treated with i.c.v. injected LPS (2 g, in 2 l sterile saline). The numbers of rolling (A) and adhesive (B) leukocytes were counted by intravital microscopy 4 h after LPS injection. SphK2 deficiency significantly reversed FTY720-induced downregulation of rolling and adhesion. The protein levels of P-selectin, E-selectin, and VCAM-1 were also reversed in SphK2-deficient mice (C-F). Data represent the mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001; n = 4-5 in all groups h after LPS administration. In particular, FTY720 treatment failed to protect the permeability of the BBB 4 h after LPS injection ( Fig. 4A and   B ). However, there was a very significant difference between the BBB permeability of the LPS and LPS/FTY720 cotreated mice 24 h after LPS injection ( Fig. 4C and D) .
In a systemic inflammation model induced by i.p. LPS injection, FTY720 was able to inhibit the expression of P-and E-selectins and VCAM-1 in the brain and many other organs, such as the lungs, kidneys, and livers ( Supplementary Fig. 3 ). In vitro, FTY720 was also able to directly inhibit the expression levels of P-selectin (Fig. 5A ), E-selectin (Fig. 5B) , and VCAM-1 (Fig. 5C ) in the brain endothelial cells.
FTY720 was activated by SphK2 and prevented leukocyte recruitment via S1P1
To determine whether FTY720 is activated by SphK2, SphK2-deficient mice were treated with LPS and FTY720. Intravital microscopy revealed that SphK2 deficiency significantly reversed the reduction in the number of rolling (Fig. 6A) and adherent ( (1 mg/kg). The numbers of rolling (A) and adhesive (B) leukocytes were counted by intravital microscopy 4 h after LPS injection. W123 treatment significantly reversed the inhibitory effects induced by FTY720. W123 treatment also reversed FTY720-induced inhibition of P-selectin (C), E-selectin (D), and VCAM-1 (E) mRNA expression in cerebral endothelial cells in vitro. Protein levels of these adhesion molecules inhibited by FTY720 treatment were reversed by W123 treatment as revealed using Western blot analysis (F-I). Data represent the mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001; n = 4-5 in all groups endothelial cells. 37 However, we only detected high expression levels of S1P1 mRNA in primary cerebral endothelial cells (data not shown).
W123, a competitive antagonist of S1P1, significantly reversed the downregulation of leukocyte rolling (Fig. 7A) and adhesion (Fig. 7B) induced by FTY720. W123 treatment also reversed the inhibition of the mRNA expression of different adhesion molecules, including Pselectin (Fig. 7C ), E-selectin (Fig. 7D) , and VCAM-1 (Fig. 7E ) in cerebral endothelial cells in vitro. Similarly, the protein expression levels of these adhesion molecules, inhibited by FTY720 treatment, were reversed by the W123 treatment ( Fig. 7F-I ). These data suggest that the S1P1 receptor plays an essential role in the FTY720-mediated blockade of endothelial activation.
FTY720 simultaneously blocked the activation of multiple signal molecules in brain endothelial cells
FTY720 treatment inhibited the phosphorylation of multiple signals in cerebral endothelial cells. In the PEX-100 signaling explorer array, phosphorylation ratio represents phospho value/unphospho value.
The changes in phosphorylation ratio after LPS + FTY720 treatment compared with that after LPS treatment were represented as LPS + FTY720 phosphorylation ratio/LPS phosphorylation ratio. Decreased phosphorylation of 17 sites was observed. These proteins can be classified into 4 pathways and a cutoff ratio of 88% was considered significant (Table 1) . Furthermore, we confirmed these results using western blot analysis. The upregulated expression of adhesion molecules activated by LPS is mainly mediated by the activation of nuclear transcriptional activators, NF-B and PI3K. 38 Increased phosphorylation levels of p65 and Akt were observed in LPS-treated cerebral endothelial cells. FTY720 treatment significantly inhibited phosphorylation of p65 (Fig. 8A) and Akt ( 4C ). Therefore, FTY720 treatment simultaneously affected multiple signaling pathways to effectively interfere with cerebral endothelial activation. A phospho-array was conducted to analyze the signaling phosphorylation profiles of both LPS-activated cerebral endothelial cells and endothelial cells treated with LPS and FTY720. The phosphorylation ratio was used to evaluate the difference between 2 samples. The L + F/L ratio changes = LPS + FTY720 phospho ratio/LPS phospho ratio. The results showed that the phosphorylation levels of nuclear factor B (NF-B), PI3K-Akt, mitogen-activated protein kinase (MAPK), and JAK-STAT signaling pathway proteins were differentially suppressed by FTY720 treatment.
TA B L E 1 Effects of FTY720 on LPS-activated phosphorylation of signal molecules in multiple signaling pathways
Molecule LPS phospho ratio LPS + FTY720 phospho ratio L + F/L ratio changes
DISCUSSION
As an oral therapy for multiple sclerosis, FTY720 exerts therapeutic effects by restraining lymphocytes in lymph nodes, thereby preventing autoreactive lymphocytes from entering the CNS. 29 In this study, we showed that FTY720 treatment significantly inhibited leukocyte recruitment in the CNS by affecting the activation of multiple signaling pathways in cerebral endothelial cells (Fig. 9 ). Our study thus reveals a novel mechanism that may contribute to the therapeutic effects of FTY720 in CNS inflammatory diseases.
The first novel finding of our study is that modulation of S1P receptor signaling directly inhibited cerebral endothelial activation to block leukocyte recruitment. In a previous study, we reported that microglia are sentinel cells detecting LPS for the activation, thereby inducing endothelial activation and leading to leukocyte recruitment in the CNS. 33 As a lipophilic small molecule, FTY720 could penetrate through the BBB and act on glial cells. 27 As S1P receptors are expressed on microglia and astrocytes, it is possible that FTY720
blocks leukocyte recruitment by affecting microglial activation. However, in such a robust animal model of CNS inflammatory disease induced by LPS, FTY720 was not able to alter the high levels of proinflammatory cytokines in the CNS. Therefore, it is unlikely that the reduced leukocyte recruitment is caused by compromised activation of microglia. In addition, FTY720 was able to directly act on endothelial cells and block the expression of adhesion molecules in vitro, further demonstrating that its biological impact on endothelial cells plays an essential role in the reduction of leukocyte recruitment.
FTY720 not only protects the BBB, but also reverses the damage it incurs during CNS inflammation. Moreover, FTY720 significantly blocked brain endothelial activation 4 h after LPS treatment and reversed the permeability change in the BBB 24 h after LPS i.c.v. injection or after neutrophils emigrated from CNS vessels. By contrast, endothelial activation and leukocyte-endothelial interactions were inhibited 4 h after LPS i.c.v. injection or before the neutrophils emigrated. Therefore, the inhibition of endothelial activation is likely the major cause of reduced neutrophil infiltration elicited by systemic FTY720 treatment. Unlike in lymphocytes, FTY720 may not internalize but rather act through its target receptors (S1P3 and/or S1P1) in endothelial cells. 41 In this study, W123, a competitive antagonist of S1P1, significantly reversed the effect of FTY720, suggesting that the inhibitory effect of FTY720 on LPS-induced endothelial activation is mediated by S1P1.
The expression of adhesion molecules, such as ICAM-1 and selectins, has been implicated in leukocyte-endothelial interaction in brain microvessels. 42, 43 It has been reported that endothelial cells exposed to LPS and S1P exhibit co-operative induction of ICAM-1 and E-selectin, suggesting the cross-talk between S1P receptors and TLR-4. 44 In addition, the interplay between TLR4 and S1P receptors F I G U R E 9 FTY720 affects neutrophil recruitment in LPS-induced CNS inflammation by inhibition of multiple signal pathways in endothelial cells. FTY720 was phosphorylated in vivo by sphingosine kinase II (SK2) and functioned via S1P1 to block the phosphorylation of Akt, NF-B, and STAT6 in cerebral endothelial cells. As a result, the expression levels of adhesion molecules, such as VCAM-1, P-selectin, and E-selectin, were reduced, thereby affecting neutrophil recruitment in the CNS significantly activates Akt and ERK. 44 However, FTY720 also blocked the leukocyte recruitment induced by TNF-. Therefore, TLR interference may not be the major mechanism underlying the inhibition of endothelial activation induced by FTY720.
Another interesting finding in our study is that FTY720 was able to inhibit the phosphorylation of many key signaling molecules that mediate endothelial activation, including p65, Akt, and STAT6. The activation of 2 phosphatases, PP2A and PTEN, following FTY720 treatment has been reported. 45, 46 PTEN, a suppressive phosphatase, is important in the regulation of cell migration. In gastric cancer cells, FTY720 has also been found to induce a significant increase in PTEN levels, which consequently inhibit Akt phosphorylation. 45 FTY720 has also been found to activate PP2A or PP2A-like phosphatase and the dephosphorylated Akt pathway. 46 We found that okadaic acid, a PP2A inhibitor, significantly reversed the inhibition of leukocyte recruitment induced by FTY720 (data not shown).
Therefore, it is possible that FTY720 activates PP2A, and then dephosphorylates the key activators of endothelial activation.
Nevertheless, the mechanisms underlying these differences should be further investigated.
In conclusion, the present study demonstrated that FTY720 blocks endothelial activation by simultaneously inhibiting NF-B-and PI3K-dependent endothelial activation, and as a result, leukocyte recruitment was prevented during CNS inflammation. FTY720 can therefore be considered as a potentially effective treatment for CNS inflammatory diseases. Our findings suggest that targeting endothelial S1P signaling is a promising approach to interfere with leukocyte recruitment in CNS inflammatory diseases. 
